Eli Lilly and Company(LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest News & Analysis
Lilly's Clinical and Commercial Execution Validate Multi-Franchise Strategy
Jaypirca CLL Phase 3 and Waltz Health partnership demonstrate clinical and commercial proof points supporting trillion-dollar valuation.
Lilly's Competitive Moat Expands Across Neuroscience and Ecosystem Leadership
Donanemab India approval and Philadelphia Gateway Labs validate Lilly's trillion-dollar thesis extends beyond cardiometabolic into emerging markets.
Lilly's Cardiometabolic Validation: Clinical Win Advances Trillion-Dollar Thesis
Blood thinner efficacy and trillion-dollar valuation inflection validate portfolio diversification beyond obesity, advancing manufacturing moat strategy.
Lilly's Strategic Pivot: When Price Cuts Drive Growth, Not Margin
CVS pharmacy exit, MeiraGTx gene therapy acquisition, and manufacturing moat validate unconventional pricing strategy.
Lilly's Amylin Drug and Trump Pricing Deal Signal Pipeline Flexibility
Eloralintide Phase 2 achieves 20.1% weight loss as Trump announces $149 obesity drug pricing, validating Lilly's multi-mechanism strategy.
Lilly's €2.6B Dutch Facility Signals Manufacturing Confidence
Lilly's €2.6B Netherlands facility validates management conviction in obesity market opportunity and supply chain resilience.
Analyst Consensus Elevates Lilly to Obesity Market Defender Amid Competitive Intensity
Goldman Sachs and BofA raise price targets to ~$950 as Novo's $9B Metsera bid validates obesity market opportunity and Lilly's competitive moat.
Lilly Q3 Earnings Validate Capital Deployment Strategy; Zepbound Tripling at Lower Prices
Q3 revenue jumped 54% to $17.6B with Zepbound sales nearly tripling at lower prices, confirming capital deployment confidence.
Lilly Demonstrates Operational Execution Through Retail, Capex, and R&D
Walmart retail partnership, Puerto Rico capex, and Nvidia AI partnership demonstrate Lilly's operational execution across distribution, manufacturing, and R&D.
Omvoh Validates Immunology as Core Pillar of Lilly's Multi-Franchise Strategy
Omvoh demonstrates sustained bowel urgency benefit in ulcerative colitis, validating immunology as material third franchise alongside metabolic and oncology.
Verzenio Achieves Adjuvant Survival Milestone, Validating Lilly's Multi-Franchise Strategy
Verzenio demonstrates first survival benefit in adjuvant breast cancer in 20+ years, validating Lilly's multi-franchise execution strategy.
Lilly's Oral GLP-1 Orforglipron Succeeds in Phase 3, Extending Metabolic Franchise Runway
Investigational once-daily pill demonstrates superior glycemic control in two pivotal diabetes trials, positioning Lilly to capture oral-preferring patients.
Lilly Expands into Alzheimer's Diagnostics as International Mounjaro Rollout Accelerates
FDA approves Roche-Lilly blood test for Alzheimer's while South Africa clears Mounjaro for obesity, broadening the pharmaceutical giant's therapeutic reach.
Eli Lilly's GLP-1 Drugs Fuel Growth Amid Competitive Pressure
Latest analysis reveals Eli Lilly’s strategic GLP-1 focus and diversified R&D, driving robust revenue growth and future potential.
Eli Lilly's GLP-1 Drugs: A Market-Shaping Force in 2025
This comprehensive analysis examines Eli Lilly's GLP-1 drugs market impact, strategic developments, and future growth opportunities.
Eli Lilly and Company News Update (Failed Generation)
Content generation failed - Recovery needed
Eli Lilly's Strategic Shift: Weight Loss Windfall Fuels Alzheimer's and ALS Push
Eli Lilly leverages its weight loss drug success to invest in groundbreaking Alzheimer's and ALS research, driving a strategic pivot.
Eli Lilly's Bold Moves: Weight Loss, Alzheimer's, and the Future
Eli Lilly strategically shifts to Alzheimer's and ALS, leveraging GLP-1 success. A $550M weight-loss pill investment and projected 32% revenue growth highlight potential.
Eli Lilly's 2025 Growth Strategy: Pipeline, Weight Loss & AI Impact
Eli Lilly navigates 2025 with GLP-1 therapies, strategic R&D investments, and expansion into new therapeutic areas, demonstrating innovation and long-term value creation.
Eli Lilly's Zepbound Strategy: Navigating Competition and Policy Risks
Eli Lilly strategically navigates the GLP-1 market with Zepbound price adjustments and LillyDirect, facing competition from Novo Nordisk and policy risks.
Eli Lilly's Zepbound Strategy: Pricing, Competition, Growth
Eli Lilly strategically adjusts Zepbound pricing, navigates competition with Novo Nordisk, and expands access via LillyDirect. The company's R&D pipeline extends beyond weight loss.
Eli Lilly's $27B US Investment: Tariffs, Zepbound, and Pharma Reshoring
Eli Lilly's $27B US investment signals a strategic shift amid rising demand for Zepbound and Mounjaro, addressing tariffs and bolstering supply chain resilience.
Eli Lilly's $27B US Manufacturing Push & Jaypirca's EU Approval
Eli Lilly expands US manufacturing with a $27B investment amid rising demand for Zepbound & Mounjaro. Plus, Jaypirca receives positive EU recommendation.
Eli Lilly (LLY) News: Manufacturing, Pricing, and Growth Analysis
Eli Lilly is expanding manufacturing, innovating Zepbound pricing, and competing in the GLP-1 market. Jaypirca's EU approval and ad campaigns against unapproved drugs highlight strategic moves.
Eli Lilly (LLY): GLP-1 Dominance and Dermatology Innovations
Eli Lilly (LLY) is experiencing growth and innovation across its pharmaceutical portfolio. Dermatology breakthroughs, GLP-1 dominance, and LillyDirect highlight its strategic direction.
Eli Lilly (LLY): Market Volatility and Competitive Pressures
Eli Lilly (LLY) navigates market volatility with competitive pressures from AbbVie in obesity and potential drug pricing regulations, balanced by breakthroughs in dermatology.
Eli Lilly: Mounjaro's India Launch, Financial Growth, and R&D
Eli Lilly's Mounjaro launches in India, financial growth surges, and R&D investments drive innovation. Investor confidence remains strong amid competitive dynamics.
Eli Lilly (LLY): Obesity Drugs, AI Innovation, and Growth Analysis
Eli Lilly's strategic moves in obesity drugs, AI, and global expansion drive growth. Financial analysis reveals strong revenue and net income growth, but high valuation warrants caution.
Eli Lilly (LLY): Strategic Moves, Obesity Drug Race, and Future Outlook
Eli Lilly navigates the obesity drug race with strategic acquisitions and awaits Orforglipron trial results, shaping its competitive future against Novo Nordisk.
Eli Lilly (LLY): Alzheimer's Setback, Weight-Loss Hope
Eli Lilly (LLY) navigates EU rejection of Kisunla, promising weight-loss drug Orforglipron, LillyDirect expansion, and VIG ETF inclusion amid macroeconomic challenges.
Eli Lilly (LLY): Zepbound Lawsuits, Tariffs, and Growth
Eli Lilly (LLY) navigates Zepbound lawsuits, tariff risks, and promising drug developments. A detailed analysis for investors.
Eli Lilly (LLY): Regulatory Challenges and Growth Opportunities
Eli Lilly (LLY) navigates regulatory changes, market competition, and healthcare policies. Key is Lepodisiran, a therapy that reduces heart disease risk, positioning it for growth.
Eli Lilly's Explosive Growth and Strategic Maneuvers (LLY)
Eli Lilly's 2024 financial results showed explosive growth, driven by strategic investments and pipeline success. Learn how recent acquisitions, regulatory milestones, and industry trends impact LLY.
Eli Lilly's 2025 Financials: Growth, Strategy, and GLP-1 Dynamics
Eli Lilly's strategic moves in 2025, from robust financial performance and pipeline expansion to navigating GLP-1 safety concerns and innovative AI collaborations.
Eli Lilly (LLY): Q4 2024 Earnings, GLP-1 Safety, and Strategic Growth
Eli Lilly's stock surged past $812, fueled by strong financial performance and strategic moves despite new GLP-1 safety concerns. We analyze its growth, R&D, and market positioning.
Eli Lilly (LLY): Zepbound Pricing Reshapes Weight-Loss Market
Eli Lilly's aggressive Zepbound pricing and robust clinical pipeline, including eloralintide, are reshaping the weight-loss market, driving significant revenue and EPS growth.
Eli Lilly's Verve Acquisition: A Bold Gene Therapy Bet
Eli Lilly's acquisition of Verve Therapeutics for up to $1.3B signals a major shift into gene editing for cardiovascular disease. Explore LLY's strategic pivot.
Eli Lilly's Strategic Momentum: Verve Acquisition, Pipeline & Financials
Eli Lilly's strategic moves in 2025, including the Verve Therapeutics acquisition and promising pipeline advancements, are reshaping its market position.
Eli Lilly's Strategic Acquisitions & Market Expansion Drive Growth
Eli Lilly's strategic acquisition of Verve Therapeutics and expansion into India underscore its aggressive growth strategy, amidst fluctuating market dynamics.
Eli Lilly's Breakthroughs: LLY's Strategic Dominance in Diabetes & Obesity
Eli Lilly's breakthroughs in diabetes and obesity treatments, with efsitora alfa and orforglipron, underscore its strategic dominance and robust financial performance in 2025.
Eli Lilly (LLY): Pipeline Innovation Drives Soaring Net Income
Eli Lilly's strategic investments in obesity, diabetes, and gene therapy propel revenue and net income, despite massive R&D and capital expenditures.
Eli Lilly (LLY): Unpacking 2024's Monumental Financial Surge
Eli Lilly's 2024 financial results reveal a monumental surge in revenue and net income, underscoring robust strategic execution and market leadership.
Eli Lilly (LLY) Dominates Obesity Market: Blockbusters & Rivalry Deep Dive
Eli Lilly's strategic dominance in the obesity market is fueled by blockbuster drugs like Zepbound and a robust pipeline, intensifying its rivalry with Novo Nordisk.
Eli Lilly (LLY) Market Update: Obesity Pipeline Leadership and Strategic Growth Insights
Eli Lilly's obesity pipeline drives growth with Orforglipron, Retatrutide, and Zepbound, supported by robust financials and strategic diversification.
Eli Lilly's Strategic Growth and Market Leadership in Metabolic and Gene Therapy - Monexa AI
Eli Lilly's robust growth driven by tirzepatide sales, gene therapy expansion, and strong financials position it as a future healthcare leader.
Eli Lilly's Market Leadership and Financial Strength in Obesity and Beyond | Monexa AI Analysis
Eli Lilly dominates the obesity drug market with Zepbound, robust pipeline, and strong financials, outpacing Novo Nordisk amid strategic diversification.
Eli Lilly's Strategic Growth and Financial Strength in the Expanding GLP-1 Market | Monexa AI
Eli Lilly's GLP-1 leadership, Verve acquisition, and strong financials underpin its growth amid evolving pharma tariffs and competitive pressures.
Eli Lilly Q2 2025 Earnings: Zepbound Growth and Strategic Expansion Insights | Monexa AI
Eli Lilly's Q2 2025 earnings highlight Zepbound's market dominance, Kisunla's Alzheimer promise, and strategic growth amid tariff risks. Detailed financial analysis inside.
Eli Lilly (LLY) Strategic Market Leadership and Financial Strength in Obesity and Metabolic Health
Eli Lilly’s robust obesity drug portfolio and pipeline fuel strong revenue growth, while strategic acquisitions diversify its market presence and financials remain solid.
Eli Lilly and Company (LLY) Market Analysis: GLP-1 Leadership and Strategic Growth Drivers
Eli Lilly's robust GLP-1 franchise, strategic acquisitions, and strong financials underpin its growth, positioning LLY as a leader in diabetes, obesity, and Alzheimer's markets.
Eli Lilly and Company (LLY) Market Leadership and Financial Performance Amid GLP-1 Expansion
Eli Lilly's GLP-1 dominance with Mounjaro and Zepbound drives strong financial growth, backed by a diversified pipeline and strategic acquisitions.
Eli Lilly's 2025 Strategy: Clinical Data, Regulation, and Financials
Eli Lilly navigates strategic collaborations, clinical data readouts, and regulatory shifts in 2025, driving significant financial and market movements.
Eli Lilly and Company Market Update: Jaypirca Trial Success and Financial Momentum Amid BTK Inhibitor Competition
Eli Lilly's Jaypirca outperforms Imbruvica in a pivotal trial, reshaping the BTK inhibitor market and driving robust financial growth in 2024.
Eli Lilly (LLY) Q2 2025 Earnings Preview: Mounjaro Surge, Donanemab Advances, and Pricing Policy Impact
Eli Lilly's Q2 2025 earnings preview highlights robust Mounjaro sales, Alzheimer's drug progress, and US drug pricing policy challenges shaping its financial outlook.
Eli Lilly (LLY) Q2 2025 Analysis: GLP-1 Market Surge, Financial Strength, and Strategic Positioning
Explore Eli Lilly's Q2 2025 performance, GLP-1 market dynamics against Novo Nordisk, and robust financials underpinning its pharma leadership.
Eli Lilly Q2 2025 Analysis: Orforglipron Trial Impact and Strong Core Growth
Eli Lilly's Q2 2025 saw a strong revenue beat amid orforglipron trial setbacks, driven by Mounjaro and Zepbound sales. Strategic pipeline and financials offer mixed signals.
Eli Lilly and Company — Earnings, R&D Intensity, and Capital Allocation Analysis
Eli Lilly’s FY2024 saw **net income more than double** and R&D surge, forcing a trade-off between reinvestment and near‑term cash conversion — a decisive signal for investors.
Eli Lilly (LLY) — Income, Cash Flow & Balance Sheet Review
FY2024 revenue rose to $45.04B (+32.01%) and net income doubled to $10.59B, but heavy capex and working-capital build compressed free cash flow to $0.41B and pushed net debt to $30.38B.
Eli Lilly (LLY): Financial Pulse — Revenue Surge, Cash-Flow Strain, Rising Leverage
FY2024 revenue jumped to $45.04B (+32.00%) while net income doubled to $10.59B (+102.14%). Free cash flow collapsed to $0.41B on heavy capex and M&A, and net debt roughly doubled to $30.38B.
Eli Lilly's Donanemab EMA Approval Boosts Alzheimer's Market Position and Pipeline Growth - Monexa AI Analysis
Eli Lilly's donanemab secures EMA positive opinion, positioning the company for significant European Alzheimer's market share and strengthening its diversified pharmaceutical pipeline.
Eli Lilly and Company: In-Depth Market Analysis and Growth Strategy Update 2025
Explore Eli Lilly's financial performance, strategic growth in GLP-1 therapies, and market positioning amid evolving pharmaceutical trends in 2025.
Eli Lilly (LLY): GLP‑1 Surge Powers +32.00% Revenue Growth, but Cash Flow and Capex Demand Close Scrutiny
Eli Lilly delivered **$45.04B** revenue in FY2024 (+32.00%), powered by GLP‑1s and a guidance lift; strong margins mask compressed free cash flow after heavy capex.
Eli Lilly (LLY): Revenue Surge, Margin Expansion and Launch Readiness
LLY posted **FY2024 revenue of $45.04B (+32.00% YoY)** and **net income of $10.59B (+102.08% YoY)** while heavy capex compressed FCF to **$414M**. Orforglipron and retatrutide are the next execution tests.
Eli Lilly and Company: Earnings, Tirzepatide Power, and the Cash-Flow Puzzle
Eli Lilly reported **$45.04B** revenue and **$10.59B** net income in FY2024 (+32.00% and +102.08% YoY) as tirzepatide momentum clashes with heavy capex and tight free cash flow.
Eli Lilly (LLY): GLP‑1 Surge, CapEx Strain and the Cash‑Flow Inflection Investors Must Track
Lilly’s GLP‑1 boom lifted revenue to **$45.04B** in 2024 and Q2 2025 GLP‑1 sales exceeded **$8.57B** — but heavy capex and working‑capital drag compress free cash flow.
Eli Lilly's Financial Strength and Strategic Growth in 2025
Eli Lilly's strategic moves in oncology and cardiometabolic health, coupled with strong financial performance, position it for continued growth.
Eli Lilly (LLY): 2024 Profit Surge Meets TuneLab AI Ambition
Eli Lilly posted **FY2024 revenue +32% to $45.04B** and **net income +102% to $10.59B**, while launching TuneLab — an AI discovery platform that reframes R&D optionality.